ArticleBioengineered2015
Engineering Ashbya gossypii for efficient biolipid production.
Article in Bioengineered, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Pioneering microbial synthesis of gangliosides in the filamentous fungus Ashbya gossypii.Biotechnology for biofuels and bioproducts · 2025Article
- Metabolic engineering of Ashbya gossypii for limonene production from xylose.Biotechnology for biofuels and bioproducts · 2022Article
- Recent advances in metabolic engineering of microorganisms for advancing lignocellulose-derived biofuels.Bioengineered · 2022Review
- New Promoters for Metabolic Engineering ofJournal of fungi (Basel, Switzerland) · 2021Article
- Aspergillus fumigatus AR04 obeys Arrhenius' rule in cultivation temperature shifts from 30 to 40°C.Microbial biotechnology · 2021Article
- The Potential of Single-Cell Oils Derived From Filamentous Fungi as Alternative Feedstock Sources for Biodiesel Production.Frontiers in microbiology · 2021Review
- Sporulation inJournal of fungi (Basel, Switzerland) · 2020Review
- One-vector CRISPR/Cas9 genome engineering of the industrial fungus Ashbya gossypii.Microbial biotechnology · 2019Article
- CRISPR/Cas9 genome editing technology in filamentous fungi: progress and perspective.Applied microbiology and biotechnology · 2019Review
- New biotechnological applications for Ashbya gossypii: Challenges and perspectives.Bioengineered · 2017Review
- Bioproduction of riboflavin: a bright yellow history.Journal of industrial microbiology & biotechnology · 2017Review
- Engineering Ashbya gossypii strains for de novo lipid production using industrial by-products.Microbial biotechnology · 2017Article
- Integrating Cellular and Bioprocess Engineering in the Non-Conventional YeastFrontiers in bioengineering and biotechnology · 2017Review
- Utilization of xylose by engineered strains ofBiotechnology for biofuels · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ashbya gossypii is a filamentous fungus that naturally overproduces riboflavin. Indeed, engineered strains are currently used for the industrial production of riboflavin, replacing the chemical synthesis processes formerly used. The utilization of A. gossypii for biotechnological applications affords significant advantages that involve low-cost media use and cheap downstream processing for some applications. Although A. gossypii cannot be considered a bona fide oleaginous microorganism, the accumulation of lipid droplets within hyphae has been described. In view of the genomic and molecular tools available for its manipulation, the metabolism of A. gossypii was engineered aiming to increase total lipid accumulation. Blocking the β-oxidation pathway through the knock-out of the AgPOX1 gene was sufficient to obtain strains with high lipid yields, comparable to those of the best oleaginous microorganisms. Thus, the poxΔ strain of A. gossypii constitutes a novel promising tool for the production of microbial oils in forthcoming modified A. gossypii strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.